打开APP

Abbott赞助Epizyme关于癌症表观遗传学药物的研发

  1. Abbott
  2. Epizyme
  3. 癌症

来源:生物谷 2013-04-21 10:26

2013年4月21日讯 /生物谷BIOON/ --Abbott公司计划和Epizyme公司合作开发一种治疗白血病的药物,这项药物的主要成分是EPZ-5676。在协议中,Epizyme将着力开发治疗混合谱系白血病(MLL)的表观遗传学药物,而同时Abbott将开发一种能够检测MLL基因突变的FISH检验方法,这种方法将有助于Epizyme更好的将新药匹配至合适的病人身体上。

2013年4月21日讯 /生物谷BIOON/ --Abbott公司计划和Epizyme公司合作开发一种治疗白血病的药物,这项药物的主要成分是EPZ-5676。在协议中,Epizyme将着力开发治疗混合谱系白血病(MLL)的表观遗传学药物,而同时Abbott将开发一种能够检测MLL基因突变的FISH检验方法,这种方法将有助于Epizyme更好的将新药匹配至合适的病人身体上。

一直到目前为止,风投公司和制药企业共投资了一亿八千万美元以支持Epizyme公司的研发过程。(生物谷Bioon.com)

详细英文报道:

Abbott ($ABT) plans to develop a companion diagnostic test for an experimental leukemia drug from the biotech startup Epizyme. The agreement follows the start of a Phase I study of the compound, EPZ-5676, for which biotech giant Celgene ($CELG) has partnered with the startup for development outside the U.S.

In September, Cambridge, MA-based Epizyme began an initial clinical trial of the compound, which aims to block the DOTIL histone methyltransferase to treat patients with a subtype of acute leukemias called mixed lineage leukemia (MLL). In adults with the MLL subtype of acute myeloid leukemia, according to Epizyme, only 5% to 24% of adult patients survive 5 years. And to identify genetically qualified patients, Abbott is going to develop a FISH test that hones in on MLL genetic alterations. This will help Epizyme match its drug with the right patients as development continues.

Epizyme, a 2011 Fierce 15 company, has a lot riding on EPZ-5676, which is the most advanced compound in the young company's pipeline and the centerpiece of its marquee partnership with Celgene. Last April Celgene forked over $90 million upfront to partner with Epizyme on the candidate and other compounds against HMT targets. As with most such pacts, Celgene will pay the bulk of potential money to Epizyme based on success in clinical trials and beyond.

Venture investors and pharma players have pumped more than $180 million into Epizyme's mission to discover and develop drugs that target epigenetic enzymes, which play roles in orchestrating gene expression that drives tumor growth. The company has brought in about $120 million in partnership income from GlaxoSmithKline ($GSK), Eisai and more recently Celgene.

Celgene has shown a willingness to bet heavily on biotech startups that the company deems to be pioneering in specific areas of cancer drug research. The drugmakers also has expansive alliance with Agios Pharmaceuticals focused on cancer metabolism drugs. And there's surely more to come.

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->